Professor Quentin Anstee is an Academic Hepatologist based in the Institute of Cellular Medicine, Newcastle University, UK. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at the Freeman Hospital, Newcastle. His translational research focuses on the pathogenesis, risk stratification and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and in particular the study of genetic and epigenetic modifiers of progressive liver disease. He is actively involved in biomarker discovery projects that will assist in the diagnosis, risk stratification and monitoring of patients with NAFLD and several ongoing clinical trials examining new medical therapies.
Prof Anstee is co-ordinator and principal investigator of the EU Horizon 2020 funded ‘EPoS’ Elucidating Pathways of Steatohepatitis consortium and European NAFLD Registry. He oversaw the FP7 Fatty Liver Inhibition of Progression 'FLIP' consortium genetic work package, led the IMPC/MRC UK Genetics of Liver Disease ‘UK GoLD’ consortium and co-founded the UK-NAFLD clinical research network. He was the recipient of a HEFCE Clinical Senior Lecturer Award, an MRC Clinical Research Fellowship and has received grant funding from the MRC, European Commission, Academy of Medical Sciences/Wellcome Trust and industrial partners.